Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ mBC

Sandra Swain • 8 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Docetaxel Pertuzumab Trastuzumab
CLEOPATRA

Sandra Swain, MD, FACP, Georgetown University Medical Center, Washington, DC, discusses CLEOPATRA (NCT00567190), a phase III, randomized, double-blind, placebo-controlled study of first-line pertuzumab, trastuzumab, and docetaxel in patients with HER2+ metastatic breast cancer (mBC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Sandra Swain

2:43
CLEOPATRA & EMILIA: HER2+ mBC state-of-the-art
Sandra Swain • 7 May 2020
1:56
NSABP B-41: genes and signatures associated with pCR
Sandra Swain • 7 May 2020
2:37
Remarkable data: trastuzumab deruxtecan for HER2+ BC
Sandra Swain • 13 May 2020
1:37
Breast cancer: SAFE-HEaRt study
Sandra Swain • 3 Jun 2019

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals